A consortium of pharmaceutical companies, academic researchers and analytical development specialists has secured a £660,000 grant from the Technology Strategy Board, the UK’s innovation agency, towards a £1 million project aimed at accelerating paediatric formulation development through smart design and predictive science.
Led by AstraZeneca, the UK-wide consortium includes Columbia Laboratories subsidiary and pharmaceutical analytical-development specialist Molecular Profiles; the not-for-profit Academy of Pharmaceutical Sciences; Pfizer, Bristol-Myers Squibb and GlaxoSmithKline; and academic institutions such as University College London, the University of Bath, the University of Birmingham and Aston University.
As Molecular Profiles pointed out, developing paediatric formulations is a more complex proposition than formulation development for adult medicines. As well as taking into account differences in physiology and anatomy, paediatric formulations have to offer flexible dosing and effective taste-masking.
This consortium will address the need for improved speed, cost and quality of paediatric formulation by drawing on the combined expertise of its members. The goal is to deliver a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy for paediatric medicines.
The government-backed Technology Strategy Board has awarded more than £9.2 million in support of 35 collaborative projects to advance the UK’s capabilities in formulated products, Molecular Profiles noted.
The funding allocated through the Formulated products - meeting the product and process design challenge was shared by 19 feasibility projects and 16 collaborative R&D projects.
The Board’s initial comnitment was increased by 50% due to the strength of the submissions, Molecular Profiles said.